Does KRRO pay a dividend?

The cached stock data on this page does not show a positive dividend yield for KRRO. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does KRRO stock do?

Pre-commercial biotechnology firm developing genetic therapeutics via its proprietary OPERA RNA editing platform, generating sporadic revenues through research collaborations and licensing milestones.

What is KRRO stock's price target?

This cached page does not contain a precise model fair value for KRRO.

The TradeMates model verdict for KRRO is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.

Is KRRO a good dividend stock?

KRRO is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

KRRO (KRRO) Stock Analysis

Q: Is KRRO stock a good investment?

The cached TradeMates AI model rates KRRO as AVOID with an investment score of 38/100. The AI model evaluates Korro Bio (KRRO) as an AVOID at $13.20 USD due to an imminent funding shortfall. Annual FCF burn of -$79.1M against $21.8M in reported cash implies under 4 months of runway without capital raises, making secondary dilution highly probable. This is algorithmic model output, not personal investment advice.

Verdict: AVOID

RNA editing pipeline offers high-upside clinical optionability, but severe cash burn ($79M FCF) and imminent dilution risk limit near-term upside.

Investment score: 38/100

The AI model evaluates Korro Bio (KRRO) as an AVOID at $13.20 USD due to an imminent funding shortfall. Annual FCF burn of -$79.1M against $21.8M in reported cash implies under 4 months of runway without capital raises, making secondary dilution highly probable.

View the full interactive analysis